2024 biotech funding tracker: recent highlights …molecules Antiverse (United Kingdom): £3.5 million ($4.6 million) seed | AI antibody design platform Ikarovec (United Kingdom): £5 million seed | gene therapy | preclinical in geographic atrophy Archon Biosciences… February 23, 2024 - 1 minutemin - By Aurore Michelin Share WhatsApp Twitter Linkedin Email
In Depth 29 Nov 2016 The ABCs of ADCs: A Review of Antibody Drug Conjugates Antibody therapies have a little sister who is catching up in funding – and hype? In light of now five deaths from Juno’s CAR-T therapy, antibody drug conjugates are attracting… November 29, 2016 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2023 Hummingbird Bioscience and Synaffix to develop ADC program …spanning initial discovery through clinical development. The company is currently developing two clinical-stage assets: HMBD-001, a humanized anti-HER3 monoclonal antibody targeting a novel epitope on HER3, and HMBD-002, a humanized… January 5, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 Feb 2024 Fourteen biotech companies spearheading the antibody drug conjugate industry The antibody-drug conjugate (ADC) field is witnessing an expansion in the variety of conjugation techniques, linker chemistry, and payloads being used, moving beyond traditional tubulin inhibitors to include novel mechanisms… February 8, 2024 - 18 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 Absolute Biotech launches as unified antibody company …well as custom antibody sequencing, antibody engineering and recombinant antibody expression services. Brands within the Absolute Biotech family are: Absolute Antibody, LSBio, Kerafast, Nordic-MUbio, Everest Biotech, and Exalpha. Absolute Biotech… October 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Nov 2024 Six bispecific antibody companies you should know about …$300 million at the end of October 2024 to acquire Chimagen Bioscience’s bispecific antibody that it believes has the potential to treat autoimmune diseases like lupus. Consequently, the bispecific antibody… November 19, 2024 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 28 May 2025 Myasthenia gravis treatments: what’s on the horizon? …in the clinic to check off clearance for yet another rare autoimmune disease, myasthenia gravis. Amgen-owned Uplizna, or inebilizumab, is a humanized IgG1 monoclonal antibody that works by targeting the… May 28, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 10 Jun 2024 ASCO 2024: The latest advances in oncology clinical trials …collaboration with Merck adds to the conversation. Leveraging Moderna’s mRNA technology, the two pharma giants are developing a regimen that involves the personalized therapy mRNA-4157 and Merck’s humanized antibody Keytruda… June 10, 2024 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 8 May 2017 The EU Approves New Treatment for a Rare Pediatric Cancer …Human Use (CHMP) has now given a positive opinion on APN311, recommending the approval of the new drug. APN311 is a monoclonal antibody targeting the neuroblastoma-specific antigen GD2. The antibody… May 8, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2024 Top biotech deals of November 2024 …part of this wintry time. Moreover, biotech deals in antibody-drug conjugates, small molecules, antibody therapies, GLP-1 agonists, and precision medicine stood out in November 2024. Table of contents Top M&As… December 12, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2022 Positive antibody persistence for vaccine treating mosquito disease …anticipated long-term durability of the antibody response after a single vaccination. Dedicated antibody persistence The antibody persistence trial enrolled 363 healthy adult participants and followed them from month six after… December 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2022 Sanyou and KangaBio to collaborate on antibody drug development and innovation …more than 40 core innovation technology platforms, including platforms for innovative antibody drug discovery with a series of trillion-level phage display antibody libraries, antibody drug optimization, cell line construction, upstream… August 29, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email